Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
68.5M
-
Shares change
-
+4.47M
-
Total reported value, excl. options
-
$630M
-
Value change
-
+$39.2M
-
Put/Call ratio
-
0
-
Number of buys
-
56
-
Number of sells
-
-48
-
Price
-
$9.19
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2023
118 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q1 2023.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.5M shares
of 128M outstanding shares and own 53.54% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (13.4M shares), BROWN CAPITAL MANAGEMENT LLC (8.6M shares), BlackRock Inc. (8.29M shares), VANGUARD GROUP INC (7.89M shares), HHLR ADVISORS, LTD. (7.7M shares), STATE STREET CORP (2.06M shares), GEODE CAPITAL MANAGEMENT, LLC (1.87M shares), MACQUARIE GROUP LTD (1.72M shares), NEW YORK STATE COMMON RETIREMENT FUND (1.38M shares), and PERCEPTIVE ADVISORS LLC (1.29M shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.